Table 1.

Postconsolidation or premaintenance depth of response across studies

Study≥VGPR, %MRD negativity (10−5), %
VRD ×8 IFM 20094  69 ∼28
(21 at 10−6) 
VRD ×3/ASCT/VRD ×2 IFM 20094  79 ∼40
(30 at 10−6) 
VRD ×6/ASCT/VRD ×2 GEM12MENOS6513,14 75 57 
VTD ×4/ASCT/VTD ×2 CASSIOPEIA16  78 44 
D-VTD ×4/ASCT/D-VTD ×2 CASSIOPEIA16  84 64 
VRD ×4/ASCT/VRD ×2 GRIFFIN30  73 17 
D-VRD ×4/ASCT/D-VRD ×2 GRIFFIN30  91 47 
KRD ×12 FORTE5  87 54 
KRD ×4/ASCT/KRD ×4 FORTE5  89 58 
D-KRD ×8 MANHATTAN33  95 77 
Study≥VGPR, %MRD negativity (10−5), %
VRD ×8 IFM 20094  69 ∼28
(21 at 10−6) 
VRD ×3/ASCT/VRD ×2 IFM 20094  79 ∼40
(30 at 10−6) 
VRD ×6/ASCT/VRD ×2 GEM12MENOS6513,14 75 57 
VTD ×4/ASCT/VTD ×2 CASSIOPEIA16  78 44 
D-VTD ×4/ASCT/D-VTD ×2 CASSIOPEIA16  84 64 
VRD ×4/ASCT/VRD ×2 GRIFFIN30  73 17 
D-VRD ×4/ASCT/D-VRD ×2 GRIFFIN30  91 47 
KRD ×12 FORTE5  87 54 
KRD ×4/ASCT/KRD ×4 FORTE5  89 58 
D-KRD ×8 MANHATTAN33  95 77 

Bold type indicates rates of VGPR >80% or MRD negativity >60%.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal